The Company's product candidates AGX8 and AGX51 are proprietary small
molecule inhibitors of the pro-angiogenic Id proteins. Extensive research and
numerous major scientific publications by researchers at Memorial Sloan
Kettering Cancer Center, led by Dr.
Dr. Garland, who designed and directed the pre-clinical studies, stated that, "These results confirm the "drugability" of the Id proteins as new and promising anti-tumor targets allowing the Company to move forward to bring the anti-Id molecules into the clinic. The data from the in vitro and in vivo studies not only validate our screening strategy but also confirm their mode of action, a major milestone required for IND filing," he added. "The proprietary small molecule inhibitors of the Id proteins are unlikely to cause serious adverse effects in patients since the main function of the Id proteins is to cause blood vessel formation in the developing fetus and they are not required for the normal activity of the vast majority of cells in the adult. Their major function in adults is to promote blood vessel formation into tumors." As for the next steps, "The program is proceeding with a number of additional in vivo studies including tests in tumor models," according to Dr. Garland, "We will be scrutinizing the data from those tests within the next two or three months as we move these drugs towards the clinic."
Company Profile:
AngioGenex, Inc. is actively engaged in the discovery, acquisition and
development of anti-cancer molecules that act by inhibiting either the Id
genes or proteins to prevent the formation of new blood vessels into tumors
(angiogenesis). The Company's technology is based on the research of Dr.
This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the ability of AngioGenex to raise subsequent, substantial additional financing, to complete clinical development of AngioGenex products, and the ability of the Company to successfully develop and market AngioGenex products and technologies. These statements represent the judgment of management as of this date and are subject to risks and uncertainties that could materially affect the Company. AngioGenex undertakes no obligation to publicly release the results of any revisions to such forward-looking statements that may be made to reflect recent events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE AngioGenex, Inc.